Inmune Bio Inc (INMB) Stock Price, Quote & News

Company Profile

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of b...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 964 3720

Website: www.inmunebio.com

Address:

225 NE Mizner Blvd., Suite 640, Boca Raton, United States

Drillbig1 Sep. 17 at 2:58 PM

$INMB POS

0 · Reply

MTRADe_01 Sep. 16 at 4:53 AM

$INMB if it holds 1.80 then a high starter position is in the works let’s goooo

0 · Reply

TEARBEARCARES Sep. 15 at 8:56 PM

$INMB Well I bought 20K shares....doing my part lets break $3

0 · Reply

alexx013 Sep. 15 at 7:07 PM

$INMB added @ 1.96

0 · Reply

Djdanny Sep. 15 at 4:26 PM

$INMB red after news like this .lol

1 · Reply

chucksters Sep. 15 at 3:41 PM

$INMB ok everyone lets start grinding up.. got rid of the weak hands lets go grind up

0 · Reply

CcBuyer Sep. 15 at 2:05 PM

$INMB INmune Bio Completes First Full-Scale Pilot Commercial Manufacturing Run Of CORDStrom, Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Therapy, For Treatment Of RDEB

0 · Reply

trading_insight Sep. 15 at 1:38 PM

$INMB is running Here we go

0 · Reply

agirlwithnoname Sep. 15 at 1:29 PM

$INMB Yikes from 14% to 3%

1 · Reply

NachoBusiness Sep. 15 at 1:06 PM

$INMB I prefer the volume disappear and we grind up

0 · Reply

INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:00 AM EDT - 6 weeks ago

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Jul 31, 2025, 7:00 AM EDT - 7 weeks ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Jul 29, 2025, 7:00 AM EDT - 7 weeks ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

Jul 4, 2025, 11:48 PM EDT - 2 months ago

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

Jul 4, 2025, 9:20 AM EDT - 2 months ago

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Jun 30, 2025, 4:05 PM EDT - 2 months ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

Jun 30, 2025, 11:52 AM EDT - 2 months ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Jan 2, 2025, 8:52 AM EST - 9 months ago

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

Dec 30, 2024, 3:20 PM EST - 9 months ago

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

Dec 4, 2024, 9:00 AM EST - 10 months ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 8:09 PM EDT - 11 months ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

INmune Bio Announces $13.0 Million Registered Direct Offering

Sep 13, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Jul 25, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Jul 23, 2024, 8:45 AM EDT - 1 year ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

Jul 8, 2024, 6:12 AM EDT - 1 year ago

0 · Reply

MTRADe_01 Sep. 16 at 4:53 AM

$INMB if it holds 1.80 then a high starter position is in the works let’s goooo

0 · Reply

TEARBEARCARES Sep. 15 at 8:56 PM

$INMB Well I bought 20K shares....doing my part lets break $3

0 · Reply

alexx013 Sep. 15 at 7:07 PM

$INMB added @ 1.96

0 · Reply

Djdanny Sep. 15 at 4:26 PM

$INMB red after news like this .lol

1 · Reply

chucksters Sep. 15 at 3:41 PM

$INMB ok everyone lets start grinding up.. got rid of the weak hands lets go grind up

0 · Reply

CcBuyer Sep. 15 at 2:05 PM

$INMB INmune Bio Completes First Full-Scale Pilot Commercial Manufacturing Run Of CORDStrom, Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Therapy, For Treatment Of RDEB

0 · Reply

trading_insight Sep. 15 at 1:38 PM

$INMB is running Here we go

0 · Reply

agirlwithnoname Sep. 15 at 1:29 PM

$INMB Yikes from 14% to 3%

1 · Reply

NachoBusiness Sep. 15 at 1:06 PM

$INMB I prefer the volume disappear and we grind up

0 · Reply

bioinvestorrr Sep. 15 at 12:48 PM

$INMB nice

0 · Reply

Rybod30 Sep. 15 at 12:43 PM

$INMB Decent news, volume gone, oh well🤷‍♂️😬..

0 · Reply

NachoBusiness Sep. 15 at 12:37 PM

$INMB 8:30 platforms that had preset sales was why it dumped

0 · Reply

Rybod30 Sep. 15 at 12:34 PM

$INMB Spread sucks..

1 · Reply

NachoBusiness Sep. 15 at 12:31 PM

$INMB that didn’t last long

0 · Reply

NachoBusiness Sep. 15 at 12:26 PM

$INMB volume is not very high Scanners haven’t pick it up yet

0 · Reply

Rybod30 Sep. 15 at 12:24 PM

$INMB Vwap looks doubtful….

0 · Reply

Mjcwo Sep. 15 at 12:19 PM

$INMB go time, give us the $10 this deserves….

0 · Reply

Rybod30 Sep. 15 at 12:18 PM

$INMB $2.30….

0 · Reply

Rybod30 Sep. 15 at 12:17 PM

$INMB Volume…

0 · Reply

fancykingz Sep. 15 at 12:12 PM

$INMB

0 · Reply

alexx013 Sep. 15 at 12:11 PM

$INMB great news

0 · Reply

Market Cap	52.90M
Revenue (ttm)	10,000.00
Net Income (ttm)	-42.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-420,800.03%
Debt to Equity Ratio	0.00

Volume	578,700
Avg Vol	1,806,458
Day's Range	N/A - N/A
Shares Out	26.59M
Stochastic %K	49%
Beta	1.03
Analysts	Sell
Price Target	$9.65